From healthy exam habits to chapter-wise preparation, paper-presentation tips, and an effective time-management plan, here’s ...

ArriVent BioPharma's furmonertinib demonstrates robust efficacy, CNS penetration, and tolerability in early trials. Read why ...

Listen and subscribe to Morningstar’s The Long View from your mobile device: Apple Podcasts | Spotify Today on the podcast we ...

Madrigal’s Rezdiffra tops $1B run-rate in MASH, but losses and rising GLP-1/FGF21 competition may cap upside into 2026. See ...